Neil Littman

Neil Littman is the Founder, CEO, and Managing Director of Bioverge Ventures, a venture capital firm focused on healthcare innovations at the intersection of biology and technology. He previously served as Head of the Therapeutics Group at CIRM, managing over 40 clinical-stage therapies valued above $500 million. During his tenure, he oversaw investments in companies like Forty Seven, acquired by Gilead for four billion nine hundred million dollars, and Cellular Dynamics International, acquired by Fujifilm for $307 million. His earlier career includes serving as Vice President of Business Development at Notable Labs and as a healthcare investment banker at Deutsche Bank and Thomas Weisel Partners with transactions exceeding $1 billion. Littman holds a Master of Science in Biotechnology from Johns Hopkins University and a Bachelor of Arts in Molecular, Cellular and Developmental Biology from University of Colorado Boulder.